Asad Fraser, MD
Rheumatology · Bowling Green, KYNPI 1497759286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $260,745 of the $354,611 with a category attached, or 73.5%. 37 manufacturers reported payments, led by Amgen at 42.9% of the total. Reporting peaked in 2019 at $134,470 and has fallen 63.8% since, to $48,737 in 2025. Among rheumatology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,474 payments — averaging $240.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$152K
- Mallinckrodt Hospital Products Inc.$70K
- Novartis$60K
- Mallinckrodt Enterprises LLC$32K
- Bristol Myers Squibb$14K
- Pfizer$8K
- plus $18K from 31 others
Across 160 payments — averaging $2199.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$211K
- GSK$58K
- Pfizer$47K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Teva Pharmaceuticals USA, Inc.$8K
- UCB SA$6K
- plus $10K from 6 others
What the payments were for
- Consulting fees$25,7087%
- Speaking & faculty fees$260,74574%
- Travel & lodging$37,78211%
- Food & beverage$30,0598%
- Education$2770%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 469 | $152,133 |
| Mallinckrodt Hospital Products Inc. | 122 | $70,436 |
| Novartis | 149 | $59,548 |
| Mallinckrodt Enterprises LLC | 32 | $31,920 |
| Bristol Myers Squibb | 34 | $14,222 |
| Pfizer | 59 | $8,239 |
| Johnson & Johnson(2 entities) | 104 | $6,322 |
| UCB, Inc. | 118 | $2,859 |
| AbbVie | 100 | $2,277 |
| GSK | 68 | $2,248 |
| Lilly USA, LLC | 35 | $693 |
| E.r. Squibb & Sons, L.L.C. | 37 | $593 |
| Radius Health, Inc. | 29 | $536 |
| AstraZeneca(2 entities) | 20 | $386 |
| Janssen Scientific Affairs, LLC | 3 | $325 |
| Sobi, Inc | 12 | $214 |
| Organon | 13 | $206 |
| Boehringer Ingelheim | 10 | $201 |
| Aurinia Pharma U.S., Inc. | 6 | $164 |
| Merck | 12 | $161 |
| Janssen Research & Development, LLC | 1 | $137 |
| Sanofi | 6 | $133 |
| Pacira Therapeutics, Inc. | 7 | $116 |
| ANI Pharmaceuticals, Inc. | 4 | $103 |
| Fresenius Kabi USA, LLC | 6 | $102 |
| Genentech USA, Inc. | 3 | $53 |
| Octapharma USA, Inc. | 2 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Sandoz | 2 | $36 |
| Antares Pharma, Inc. | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$354,611 in reported general payments places this provider in the 95th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 18 | $126,770 |
| XeljanzTofacitinib Citrate | 18 | $103,657 |
| RinvoqUpadacitinib | 11 | $71,677 |
| OtezlaApremilast | 13 | $62,893 |
| TymlosAbaloparatide | 14 | $37,338 |
| RasuvoMethotrexate/Pf | 14 | $7,727 |
| MethotrexateMethotrexate Sodium | 258 | $4,367 |
| Febuxostat | 26 | $3,867 |
| Gabapentin | 436 | $3,516 |
| Pregabalin | 152 | $3,096 |
| Leflunomide | 32 | $2,051 |
| Hydroxychloroquine Sulfate | 52 | $1,659 |
| Mycophenolate Mofetil | 14 | $1,482 |
| Colchicine | 24 | $1,128 |
| Prednisone | 126 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $8,239 | $103,65718 claims |
| AbbVieRinvoq | $2,277 | $71,67711 claims |
| AmgenOtezla | $152,133 | $62,89313 claims |
| Radius Health, Inc.Tymlos | $536 | $37,33814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Bowling Green
- Neha PansuriaBowling Green$39K
- Jonathan HendrieBowling Green$3K
- Rebecca CallisFlorence$272K
- Gary CrumpLouisville$176K
- Benjamin BooneLouisville$80K
- Jacquelyn SmithLouisville$63K
- Timothy LoneskySomerset$32K
- Mansoor AhmedRichmond$29K
- Liza VargheseCrestview Hills$29K
- Lisa JuneLouisville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.